Cargando…

Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression

BACKGROUND: This Phase 1b/2 study evaluated tepotinib, a highly selective MET inhibitor, in US/European patients with sorafenib pretreated advanced hepatocellular carcinoma (aHCC) with MET overexpression. METHODS: Eligible adults had aHCC, progression after ≥4 weeks of sorafenib, and, for Phase 2 on...

Descripción completa

Detalles Bibliográficos
Autores principales: Decaens, Thomas, Barone, Carlo, Assenat, Eric, Wermke, Martin, Fasolo, Angelica, Merle, Philippe, Blanc, Jean-Frédéric, Grando, Véronique, Iacobellis, Angelo, Villa, Erica, Trojan, Joerg, Straub, Josef, Bruns, Rolf, Berghoff, Karin, Scheele, Juergen, Raymond, Eric, Faivre, Sandrine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8292404/
https://www.ncbi.nlm.nih.gov/pubmed/33824476
http://dx.doi.org/10.1038/s41416-021-01334-9
_version_ 1783724825950289920
author Decaens, Thomas
Barone, Carlo
Assenat, Eric
Wermke, Martin
Fasolo, Angelica
Merle, Philippe
Blanc, Jean-Frédéric
Grando, Véronique
Iacobellis, Angelo
Villa, Erica
Trojan, Joerg
Straub, Josef
Bruns, Rolf
Berghoff, Karin
Scheele, Juergen
Raymond, Eric
Faivre, Sandrine
author_facet Decaens, Thomas
Barone, Carlo
Assenat, Eric
Wermke, Martin
Fasolo, Angelica
Merle, Philippe
Blanc, Jean-Frédéric
Grando, Véronique
Iacobellis, Angelo
Villa, Erica
Trojan, Joerg
Straub, Josef
Bruns, Rolf
Berghoff, Karin
Scheele, Juergen
Raymond, Eric
Faivre, Sandrine
author_sort Decaens, Thomas
collection PubMed
description BACKGROUND: This Phase 1b/2 study evaluated tepotinib, a highly selective MET inhibitor, in US/European patients with sorafenib pretreated advanced hepatocellular carcinoma (aHCC) with MET overexpression. METHODS: Eligible adults had aHCC, progression after ≥4 weeks of sorafenib, and, for Phase 2 only, MET overexpression. Tepotinib was administered once daily at 300 or 500 mg in Phase 1b (‘3 + 3’ design), and at the recommended Phase 2 dose (RP2D) in Phase 2. Primary endpoints were dose-liming toxicities (DLTs; Phase 1b) and 12-week investigator-assessed progression-free survival (PFS; Phase 2). RESULTS: In Phase 1b (n = 17), no DLTs occurred and the RP2D was confirmed as 500 mg. In Phase 2 (n = 49), the primary endpoint was met: 12-week PFS was 63.3% (90% CI: 50.5–74.7), which was significantly greater than the predefined null hypothesis of ≤15% (one-sided binomial exact test: P < 0.0001). Median time to progression was 4 months. In Phase 2, 28.6% of patients had treatment-related Grade ≥3 adverse events, including peripheral oedema and lipase increase (both 6.1%). CONCLUSIONS: Tepotinib was generally well tolerated and the RP2D (500 mg) showed promising efficacy and, therefore, a positive benefit–risk balance in sorafenib pretreated aHCC with MET overexpression. TRIAL REGISTRATION: ClinicalTrials.gov: NCT02115373.
format Online
Article
Text
id pubmed-8292404
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-82924042021-07-23 Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression Decaens, Thomas Barone, Carlo Assenat, Eric Wermke, Martin Fasolo, Angelica Merle, Philippe Blanc, Jean-Frédéric Grando, Véronique Iacobellis, Angelo Villa, Erica Trojan, Joerg Straub, Josef Bruns, Rolf Berghoff, Karin Scheele, Juergen Raymond, Eric Faivre, Sandrine Br J Cancer Article BACKGROUND: This Phase 1b/2 study evaluated tepotinib, a highly selective MET inhibitor, in US/European patients with sorafenib pretreated advanced hepatocellular carcinoma (aHCC) with MET overexpression. METHODS: Eligible adults had aHCC, progression after ≥4 weeks of sorafenib, and, for Phase 2 only, MET overexpression. Tepotinib was administered once daily at 300 or 500 mg in Phase 1b (‘3 + 3’ design), and at the recommended Phase 2 dose (RP2D) in Phase 2. Primary endpoints were dose-liming toxicities (DLTs; Phase 1b) and 12-week investigator-assessed progression-free survival (PFS; Phase 2). RESULTS: In Phase 1b (n = 17), no DLTs occurred and the RP2D was confirmed as 500 mg. In Phase 2 (n = 49), the primary endpoint was met: 12-week PFS was 63.3% (90% CI: 50.5–74.7), which was significantly greater than the predefined null hypothesis of ≤15% (one-sided binomial exact test: P < 0.0001). Median time to progression was 4 months. In Phase 2, 28.6% of patients had treatment-related Grade ≥3 adverse events, including peripheral oedema and lipase increase (both 6.1%). CONCLUSIONS: Tepotinib was generally well tolerated and the RP2D (500 mg) showed promising efficacy and, therefore, a positive benefit–risk balance in sorafenib pretreated aHCC with MET overexpression. TRIAL REGISTRATION: ClinicalTrials.gov: NCT02115373. Nature Publishing Group UK 2021-04-06 2021-07-20 /pmc/articles/PMC8292404/ /pubmed/33824476 http://dx.doi.org/10.1038/s41416-021-01334-9 Text en © The Author(s) 2021, corrected publication 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Decaens, Thomas
Barone, Carlo
Assenat, Eric
Wermke, Martin
Fasolo, Angelica
Merle, Philippe
Blanc, Jean-Frédéric
Grando, Véronique
Iacobellis, Angelo
Villa, Erica
Trojan, Joerg
Straub, Josef
Bruns, Rolf
Berghoff, Karin
Scheele, Juergen
Raymond, Eric
Faivre, Sandrine
Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression
title Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression
title_full Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression
title_fullStr Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression
title_full_unstemmed Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression
title_short Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression
title_sort phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with met overexpression
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8292404/
https://www.ncbi.nlm.nih.gov/pubmed/33824476
http://dx.doi.org/10.1038/s41416-021-01334-9
work_keys_str_mv AT decaensthomas phase1b2trialoftepotinibinsorafenibpretreatedadvancedhepatocellularcarcinomawithmetoverexpression
AT baronecarlo phase1b2trialoftepotinibinsorafenibpretreatedadvancedhepatocellularcarcinomawithmetoverexpression
AT assenateric phase1b2trialoftepotinibinsorafenibpretreatedadvancedhepatocellularcarcinomawithmetoverexpression
AT wermkemartin phase1b2trialoftepotinibinsorafenibpretreatedadvancedhepatocellularcarcinomawithmetoverexpression
AT fasoloangelica phase1b2trialoftepotinibinsorafenibpretreatedadvancedhepatocellularcarcinomawithmetoverexpression
AT merlephilippe phase1b2trialoftepotinibinsorafenibpretreatedadvancedhepatocellularcarcinomawithmetoverexpression
AT blancjeanfrederic phase1b2trialoftepotinibinsorafenibpretreatedadvancedhepatocellularcarcinomawithmetoverexpression
AT grandoveronique phase1b2trialoftepotinibinsorafenibpretreatedadvancedhepatocellularcarcinomawithmetoverexpression
AT iacobellisangelo phase1b2trialoftepotinibinsorafenibpretreatedadvancedhepatocellularcarcinomawithmetoverexpression
AT villaerica phase1b2trialoftepotinibinsorafenibpretreatedadvancedhepatocellularcarcinomawithmetoverexpression
AT trojanjoerg phase1b2trialoftepotinibinsorafenibpretreatedadvancedhepatocellularcarcinomawithmetoverexpression
AT straubjosef phase1b2trialoftepotinibinsorafenibpretreatedadvancedhepatocellularcarcinomawithmetoverexpression
AT brunsrolf phase1b2trialoftepotinibinsorafenibpretreatedadvancedhepatocellularcarcinomawithmetoverexpression
AT berghoffkarin phase1b2trialoftepotinibinsorafenibpretreatedadvancedhepatocellularcarcinomawithmetoverexpression
AT scheelejuergen phase1b2trialoftepotinibinsorafenibpretreatedadvancedhepatocellularcarcinomawithmetoverexpression
AT raymonderic phase1b2trialoftepotinibinsorafenibpretreatedadvancedhepatocellularcarcinomawithmetoverexpression
AT faivresandrine phase1b2trialoftepotinibinsorafenibpretreatedadvancedhepatocellularcarcinomawithmetoverexpression